Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Leases (2021 - 2025)

Historic Current Leases for Janux Therapeutics (JANX) over the last 5 years, with Q3 2025 value amounting to $2.3 million.

  • Janux Therapeutics' Current Leases rose 3499.11% to $2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 3499.11%. This contributed to the annual value of $1.7 million for FY2024, which is 1529.33% up from last year.
  • According to the latest figures from Q3 2025, Janux Therapeutics' Current Leases is $2.3 million, which was up 3499.11% from $1.9 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Current Leases high stood at $2.3 million for Q3 2025, and its period low was $88000.0 during Q2 2022.
  • Over the past 5 years, Janux Therapeutics' median Current Leases value was $1.5 million (recorded in 2023), while the average stood at $1.2 million.
  • In the last 5 years, Janux Therapeutics' Current Leases skyrocketed by 150000.0% in 2023 and then surged by 1490.8% in 2025.
  • Janux Therapeutics' Current Leases (Quarter) stood at $194000.0 in 2021, then skyrocketed by 293.3% to $763000.0 in 2022, then surged by 98.82% to $1.5 million in 2023, then grew by 15.29% to $1.7 million in 2024, then skyrocketed by 30.36% to $2.3 million in 2025.
  • Its Current Leases stands at $2.3 million for Q3 2025, versus $1.9 million for Q2 2025 and $1.8 million for Q1 2025.